A new study published in the Journal of Affective Disorders has found that adults with major depression show specific ...

A generative AI–powered therapy chatbot is linked to significant reductions in symptoms of depression, anxiety, and eating ...

A fully generative artificial intelligence (AI) therapy chatbot was effective for reducing mental health symptoms, including ...

Axsome Therapeutics, Inc. has announced the topline results of the Paradigm Phase 3 proof-of-concept trial of Solriamfetol in major depressive disorder (MDD) with and without excessive daytime ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

Axsome Therapeutics (AXSM) stock falls as its depression drug solriamfetol fails in a Phase 3 trial for those with daytime ...

Cigna's Evernorth unit is expanding coverage for Neuronetics' therapy for depression to adolescents. | Cigna's Evernorth unit ...

Discover the 6 types of depression affecting millions of Americans, their causes, warning signs, and effective treatments ...

Everyone experiences occasional ups and downs. However, dramatic mood swings and emotional instability that disrupt relationships, work or school and daily living could signal something more: ...

Neuronetics (STIM) announced that Evernorth Health Services, a wholly owned subsidiary of The Cigna Group, has expanded its coverage of ...

Study finds AI chatbot significantly improve symptoms for those suffering from major depressive disorder (MDD), generalized ...